Teleflex Inc. stock gains attention as new Dynetic-35 stent debuts at CIRSE 2026

Teleflex Inc. stock is in focus as the medical technology group showcases its new Dynetic-35 balloon-expandable stent system at the CIRSE 2026 meeting in Copenhagen, while recent quarterly figures and analyst targets frame the valuation.

Teleflex Inc. stock (ISIN US8793691069) is drawing investor attention on September 6, 2026, as the medical technology group highlights its new Dynetic-35 balloon-expandable cobalt chromium stent system at the CIRSE 2026 interventional radiology meeting in Copenhagen, according to a Business Wire release dated September 6, 2026. The company, listed on the New York Stock Exchange under the ticker TFX, combines this product push with recently reported second-quarter 2026 figures that showed earnings per share and revenue above market expectations as compiled by a major financial portal.

New stent system showcased at CIRSE 2026

According to a Business Wire industry update published on September 6, 2026, Teleflex Incorporated is presenting its Dynetic-35 balloon-expandable cobalt chromium stent system at the CIRSE 2026 meeting in Copenhagen. The release describes Teleflex as a leading global provider of medical technologies and notes that the Dynetic-35 system is one of several innovative devices the company is showcasing to interventional radiologists at the event.

The Business Wire report explains that Dynetic-35 is designed for precise placement and radial strength in challenging vascular procedures, supported by data from the investigator-initiated BIONETIC-TRA study previously presented in the interventional community. For investors, the visibility of the Dynetic-35 system at an international congress is relevant because it underlines Teleflex's strategy to drive growth through new minimally invasive technologies for hospitals and clinics.

Recent quarterly figures and analyst view

In addition to the product news, current valuation of Teleflex Inc. stock is framed by recent second-quarter 2026 results and updated analyst expectations reported by a large financial portal covering the shares. That portal cites that in the latest reported quarter, Teleflex delivered earnings per share of 1.76 USD versus a consensus forecast of 1.27 USD, meaning EPS came in 0.49 USD above expectations in the second quarter of 2026. It also reports quarterly revenue of 570.3 million USD compared with market estimates of 559.06 million USD, implying revenue exceeded the consensus by 11.24 million USD in the same period.

The same portal overview notes that, based on analyst models updated in August 2026, the average 12-month price target for Teleflex stands at 152.55 USD, with the highest target at 169 USD and the lowest at 138 USD. As of late August 2026, the shares were reported trading at 137.97 USD, which positions the average target roughly 10.6 percent above that late-August price level. One analyst house listed in the portal's table is UBS, which is shown with a hold rating and a price objective of 145.00 USD for Teleflex as of July 28, 2026, providing a reference point between the current share price and the broader target range.

Market data and trading range

Market data compiled by a major European financial portal as of August 25, 2026, show Teleflex Inc. stock trading at 137.97 USD, with a previous close at 138.31 USD as of that date. The same data indicate that on that day the intraday trading range for Teleflex ran between 136.35 USD and 137.98 USD, highlighting relatively tight day-to-day volatility in late August ahead of the September 2026 product news.

The portal further reports a 52-week low for Teleflex at 100.18 USD and a 52-week high at 145.00 USD, also as of August 25, 2026. That places the reported late-August price of 137.97 USD closer to the upper end of the 52-week band than to the low, suggesting that the shares are trading at a level not far below the reported 145.00 USD high of the last year. For investors, this combination of a strong position within the 52-week range and an analyst average target of 152.55 USD gives a quantitative frame for how the market prices Teleflex's earnings performance and innovation pipeline.

Representative product: Dynetic-35 stent system

The Dynetic-35 balloon-expandable cobalt chromium stent system, highlighted at CIRSE 2026 in Copenhagen, is a representative example of Teleflex's portfolio of interventional devices for vascular procedures. As described in the Business Wire update on September 6, 2026, Dynetic-35 is engineered for controlled deployment and radial strength in target vessels, and is supported by data from the BIONETIC-TRA study, an investigator-initiated trial that examined performance at the radial access site.

While revenue for individual products is not broken out in the available snippets, the second-quarter 2026 revenue figure of 570.3 million USD indicates that Teleflex's portfolio of devices, including stents, catheters and specialty medical technologies, continues to generate substantial top-line contributions. The upside of 11.24 million USD versus the consensus estimate of 559.06 million USD for that quarter suggests that the company is currently managing to outpace expectations at the aggregate level, which provides context for the strategic emphasis on new systems such as Dynetic-35.

Teleflex Inc. stock price context for retail investors

Teleflex Inc. stock is primarily traded on the New York Stock Exchange in USD, and investors reviewing the shares on September 6, 2026, can anchor their price assessment on the confirmed closing level of 137.97 USD as of August 25, 2026 from the European portal data. At that price the shares stood approximately 37.79 USD above the reported 52-week low of 100.18 USD and 7.03 USD below the 52-week high of 145.00 USD, giving a clear numerical measure of where the stock sits within its one-year trading corridor.

For retail investors following Teleflex from the DACH region, the stock can typically be accessed via local bank and broker platforms that route orders to the NYSE, and the combination of earnings beats for the second quarter of 2026 and the recent Dynetic-35 stent presentation at CIRSE 2026 offers a concrete, number-backed narrative behind the current valuation. As always, the key factors remain the sustainability of margin improvements implied by the earnings beat and the extent to which new products such as Dynetic-35 contribute to future revenue growth.

Teleflex Inc. stock key data

• Company: Teleflex Inc.
• ISIN: US8793691069
• Ticker: TFX
• Trading venue: NYSE
• Price (as of August 25, 2026): 137.97 USD
• Market capitalization: [value] USD (as of August 25, 2026)
• Sector / Industry: Health care equipment and supplies
• Index membership: S&P 500